GlaxoSmithKline Rating Reiterated by JPMorgan Chase & Co. (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating reiterated by equities researchers at JPMorgan Chase & Co. in a research report issued on Tuesday, Stock Ratings News reports. They currently have a GBX 1,750 ($28.84) price objective on the stock. JPMorgan Chase & Co.’s price target points to a potential upside of 6.38% from the stock’s previous close.
GlaxoSmithKline (LON:GSK) traded up 0.61% on Tuesday, hitting GBX 1645.0001. 8,981,827 shares of the company’s stock traded hands. GlaxoSmithKline has a 52-week low of GBX 1364.00 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1596. and its 200-day moving average is GBX 1630.. The company’s market cap is £79.240 billion.
GSK has been the subject of a number of other recent research reports. Analysts at UBS AG initiated coverage on shares of GlaxoSmithKline in a research note to investors on Friday, January 10th. They set a “neutral” rating on the stock. Separately, analysts at Galvan Research reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Monday, December 30th. They now have a GBX 1,700 ($28.02) price target on the stock. Finally, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, December 19th. They now have a GBX 1,500 ($24.72) price target on the stock. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of GBX 1,623.92 ($26.76).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.